Navigation Links
Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
Date:10/4/2010

BEDMINSTER, N.J., Oct. 4 /PRNewswire/ -- Archimedes Pharma US Inc. today announced publication of results from a pivotal clinical study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain (BTCP). The article, entitled "A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain," has been published in Pain, the peer-reviewed journal from the International Association for the Study of Pain.  

This randomized, placebo-controlled, double-blind study assessed the efficacy and tolerability of FPNS in cancer patients with breakthrough pain in spite of receiving adequate background opioid therapy.  The full text of the study is available at http://www.jpain.org/.

This study met its primary endpoint in demonstrating a significant difference in summed pain intensity difference 30 minutes after dosing (SPID30; p<0.0001).  In addition, significant benefits in pain intensity were noted at five minutes after dosing and were maintained to the end of the assessment period.  Adverse events in the study were typical of an opioid medication in this population.  The most frequently reported adverse events were vomiting, nausea, disease progression and constipation; the majority of such events were mild to moderate in intensity.

The trial's lead investigator, Dr. Russell Portenoy, chairman of the Department of Pain Medicine at New York's Beth Israel Hospital, said, "Both the prevalence and negative impact of breakthrough cancer pain support the need for new treatments.  A rapid onset formulation has a clear rationale, potentially addressing the well documented mismatch between the time course of most breakthrough pains and the time action relationship of oral drugs."

Jeff Buchalter, President and CEO of Archimedes Pharma, commented, "BTCP, which remains under recognized and inadequately managed, affects up to 95% of all cancer patients.  FPNS' proprietary pectin-based transmucosal delivery system is characterized by reduced time to onset of effect, which helps overcome one limitation associated with treatment by conventional opioids."  

Notes to editors:About Archimedes PharmaArchimedes Pharma is an international specialty pharmaceutical company focused on the oncology, pain, neurology, and critical care sectors. Archimedes Pharma is marketing an expanding portfolio of specialist products to hospital-based prescribers in Europe and has established commercial organizations in the UK, US, France, Germany, Ireland, and Spain.

Archimedes Pharma's portfolio includes an innovative fentanyl nasal spray, PecFent®, approved in Europe for the treatment of breakthrough cancer pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain, and is under review by the US Food and Drug Administration (FDA).

PecFent®

PecFent is an innovative fentanyl citrate nasal spray that has been granted Marketing Authorization by the European Medicines Agency for the treatment of breakthrough cancer pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

About Breakthrough Cancer Pain (BTCP)

Breakthrough cancer pain affects up to 95% of all cancer patients with pain and is characterized by sudden, unpredictable episodes of intense pain that occur despite background pain medication. This pain is rapid in onset, usually reaching maximum intensity in five minutes and lasting for 30 to 60 minutes.

For more information, please visit: www.archimedespharma.com.Media contacts:Tiberend Strategic Advisors, Inc. (USA)Tamara Bright/Andrew Mielach +1 212-827-0020 tbright@tiberendstrategicadvisors.com/amielach@tiberendstrategicadvisors.comCitigate Dewe Rogerson (UK and Europe)Chris Gardner/Amber Bielecka, +44 207 638 9571 chris.gardner@citigatedr.co.uk/amber.bielecka@citigatedr.co.uk
'/>"/>

SOURCE Archimedes Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
2. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):